{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:11:26Z","timestamp":1792145486934,"version":"4.4.0"},"reference-count":43,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1K23HL143167"],"award-info":[{"award-number":["1K23HL143167"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GUIMBE20A0-KB"],"award-info":[{"award-number":["GUIMBE20A0-KB"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GUIMBE20K0"],"award-info":[{"award-number":["GUIMBE20K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HAMBLE17K0"],"award-info":[{"award-number":["HAMBLE17K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["ZEMANI17K0"],"award-info":[{"award-number":["ZEMANI17K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>\n                      Cystic fibrosis (CF) is caused by variants in the CF transmembrane conductance regulator (\n                      <jats:italic>CFTR<\/jats:italic>\n                      ), leading to defective chloride ion transport and multiorgan dysfunction. CFTR modulators substantially improve chloride ion transport and disease severity, but responses vary, which may in part be due to variation in drug concentrations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate modulator concentrations among people with CF and the potential impact of cytochrome P450 (CYP)3A5 genotypes on sweat chloride.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre study enrolled 97 children and adult participants established on elexacaftor\/tezacaftor\/ivacaftor (ETI) therapy. ETI drug concentrations were quantified and CYP3A5 genotypes were determined. Relationship between drug concentrations, genotype, and sweat chloride response were investigated using correlation and multivariable regression models to examine associations between drug levels and sweat chloride.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and main results<\/jats:title>\n                    <jats:p>Plasma concentrations of elexacaftor, tezacaftor and ivacaftor were highly variable. Analyses revealed that CYP3A5 genotype status had no significant effect on drug concentrations. Association analysis demonstrated an association of sweat chloride with drug concentrations including after adjusting for pre-modulator sweat chloride, age, race, body mass index and sex, showing that lower drug concentrations are associated with worse outcomes in sweat chloride.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides evidence that lower drug concentration are associated with worse sweat chloride levels and may be a potential indicator of therapeutic effectiveness, especially for people with high sweat chloride despite treatment. The influence of drug variability underscores the need for personalised dosing strategies to improve CF treatment outcome, although well-known CYP3A5 genotypes are unlikely to be helpful.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01594-2025","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:35:15Z","timestamp":1771518915000},"page":"2501594","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of CFTR modulator concentrations on clinical response in cystic fibrosis"],"prefix":"10.1183","volume":"67","author":[{"given":"Ashritha R.","family":"Chalamalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Natt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith T.","family":"Zemanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Guimbellot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2026061210150645000_67.6.2501594.1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2024.12.006","article-title":"Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment","volume":"24","author":"Zemanick","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.2","unstructured":"Yu E , Sankari A , Sharma S . Cystic Fibrosis. Treasure Island (FL), StatPearls, 2025."},{"key":"2026061210150645000_67.6.2501594.3","doi-asserted-by":"crossref","first-page":"20406223221098136","DOI":"10.1177\/20406223221098136","article-title":"New drugs in cystic fibrosis: what has changed in the last decade?","volume":"13","author":"Roda","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"2026061210150645000_67.6.2501594.4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01662"},{"key":"2026061210150645000_67.6.2501594.5","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2016.10.009","article-title":"Biomarkers for cystic fibrosis drug development","volume":"15","author":"Muhlebach","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2013.08.008","article-title":"Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis","volume":"13","author":"Dalb\u00f8ge","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ppul.23638","article-title":"Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients","volume":"52","author":"Schultz","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2026061210150645000_67.6.2501594.8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/1.suppl_3.59"},{"key":"2026061210150645000_67.6.2501594.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80250-1"},{"key":"2026061210150645000_67.6.2501594.10","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835040-00004"},{"key":"2026061210150645000_67.6.2501594.11","doi-asserted-by":"crossref","first-page":"123518","DOI":"10.1016\/j.jchromb.2022.123518","article-title":"Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate","volume":"1213","author":"Ryan","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2026061210150645000_67.6.2501594.12","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/ppul.26093","article-title":"Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis","volume":"57","author":"Guimbellot","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"2026061210150645000_67.6.2501594.13","doi-asserted-by":"crossref","first-page":"102301","DOI":"10.1016\/j.pupt.2024.102301","article-title":"Pharmacokinetic variability of CFTR modulators from standard and alternative regimens","volume":"86","author":"Rose","year":"2024","journal-title":"Pulm Pharmacol Ther"},{"key":"2026061210150645000_67.6.2501594.14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061210150645000_67.6.2501594.15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jcf.2024.03.010","article-title":"Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor","volume":"23","author":"Vonk","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1164\/rccm.202407-1302OC","article-title":"Ivacaftor for chronic obstructive pulmonary disease \u2013 results from a phase 2, randomized controlled trial","volume":"211","author":"Vijaykumar","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061210150645000_67.6.2501594.17","doi-asserted-by":"crossref","first-page":"107868","DOI":"10.1016\/j.rmed.2024.107868","article-title":"Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor before, during, and after pregnancy in women with cystic fibrosis: an observational study","volume":"236","author":"Christina","year":"2025","journal-title":"Respir Med"},{"key":"2026061210150645000_67.6.2501594.18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40262-023-01342-3","article-title":"Lumacaftor\/ivacaftor population pharmacokinetics in pediatric patients with cystic fibrosis: a first step toward personalized therapy","volume":"63","author":"Bouazza","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"2026061210150645000_67.6.2501594.19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jcf.2024.02.001","article-title":"Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis","volume":"23","author":"Zemanick","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.20","unstructured":"U.S. Food and Drug Administration . Drug Approval Package: Trikafta. 2019 7\/30\/2020. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=212273"},{"key":"2026061210150645000_67.6.2501594.21","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.113"},{"key":"2026061210150645000_67.6.2501594.22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2217\/pgs.15.186","article-title":"SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma","volume":"17","author":"Duran","year":"2016","journal-title":"Pharmacogenomics"},{"key":"2026061210150645000_67.6.2501594.23","doi-asserted-by":"publisher","DOI":"10.1080\/00498250600944300"},{"key":"2026061210150645000_67.6.2501594.24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jaci.2015.02.009","article-title":"Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone","volume":"136","author":"Stockmann","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2026061210150645000_67.6.2501594.25","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.064998"},{"key":"2026061210150645000_67.6.2501594.26","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2013.67"},{"key":"2026061210150645000_67.6.2501594.27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.livres.2019.08.001","article-title":"Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism","volume":"3","author":"Wright","year":"2019","journal-title":"Liver Res"},{"key":"2026061210150645000_67.6.2501594.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.01.005"},{"key":"2026061210150645000_67.6.2501594.29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcf.2022.07.008","article-title":"Characterizing CFTR modulated sweat chloride response across the cf population: initial results from the CHEC-SC study","volume":"22","author":"Mayer-Hamblett","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.30","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jcf.2021.01.011","article-title":"Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: rationale and design of the CHEC-SC study","volume":"20","author":"Zemanick","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.31","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S2213-2600(23)00324-7","article-title":"Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy","volume":"11","author":"Hisert","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026061210150645000_67.6.2501594.32","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jcf.2025.03.010","article-title":"Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant","volume":"24","author":"Guimbellot","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.33","doi-asserted-by":"crossref","first-page":"A4085","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A4085","article-title":"One- and two-timepoint sparse sampling is highly predictive of average plasma concentration of CFTR modulators","volume":"211","author":"Abouelenein","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061210150645000_67.6.2501594.34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","article-title":"Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination elexacaftor\/tezacaftor\/ivacaftor","volume":"6","author":"Tsai","year":"2020","journal-title":"Pulm Ther"},{"key":"2026061210150645000_67.6.2501594.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201901-0145OC"},{"key":"2026061210150645000_67.6.2501594.36","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jcf.2015.01.005","article-title":"Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype","volume":"14","author":"McKone","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jcf.2025.03.008","article-title":"Real-world pharmacokinetics of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis: a prospective observational study","volume":"24","author":"Vonk","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026061210150645000_67.6.2501594.39","doi-asserted-by":"crossref","first-page":"e70245","DOI":"10.1111\/cts.70245","article-title":"Elexacaftor\/tezacaftor\/ivacaftor population pharmacokinetics in pediatric patients with cystic fibrosis","volume":"18","author":"Truong","year":"2025","journal-title":"Clin Transl Sci"},{"key":"2026061210150645000_67.6.2501594.40","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/jpm14101065","article-title":"Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor in adult people with cystic fibrosis","volume":"14","author":"Naehrig","year":"2024","journal-title":"J Pers Med"},{"key":"2026061210150645000_67.6.2501594.41","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40262-025-01516-1","article-title":"Population pharmacokinetics of elexacaftor, tezacaftor and ivacaftor in a real-world cohort of adults with cystic fibrosis","volume":"64","author":"Magnas","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026061210150645000_67.6.2501594.42","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000001014"},{"key":"2026061210150645000_67.6.2501594.43","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatr Pulmonol"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01594-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:15:21Z","timestamp":1781284521000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01594-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,12]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1183\/13993003.01594-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01594-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}